[MCK] McKesson: Q2 Fiscal 2027 Earnings Test Drug Distribution Margin Gains

McKesson is the largest US drug wholesaler by revenue, distributing prescription medicines to retail chains, independent pharmacies, hospitals and health systems, while also running community oncology and ophthalmology practice networks, prescription-access technology services for drugmakers and a medical-surgical supply business; its fiscal year ends on March 31[1]. According to the Drillr earnings calendar, the company is scheduled to hold its earnings call for the Second quarter fiscal 2027 (three months ended September 30, 2026) on 2026-11-04[2]. In the latest disclosed quarter, the first quarter of fiscal 2027, revenue rose 8% to $105.38 billion and adjusted EPS rose 20% to $9.93, while GAAP diluted EPS fell from $6.25 to $5.15 because of a $293 million redemption value adjustment on the Medical-Surgical minority interest; adjusted operating profit across the four segments totaled $1.797 billion, against $1.562 billion a year earlier[3]. The company gives only full-year guidance, not quarterly guidance: on August 5 it raised its fiscal 2027 adjusted EPS guidance from $43.80-$44.60 to $44.20-$45.00[3], and it kept full-year guidance for 5%-9% revenue growth, 9%-13% operating profit growth and $4.5-$4.9 billion of free cash flow[4]. Analyst estimates compiled by Drillr on 2026-10-22 put second-quarter adjusted EPS at $10.72 (10 analysts, range $10.56-$10.99), revenue at $109.86 billion (8 analysts) and full-year adjusted EPS at $44.64, slightly above the $44.60 guidance midpoint; for comparison, the equivalent first-quarter estimate was $9.56 against an actual result of $9.93[5][3].

Three things matter most in this McKesson earnings report. First is whether the margin expansion in North American Pharmaceutical distribution can last: the segment grew revenue only 5% in the first quarter, yet adjusted operating profit rose 19% to $894 million and the margin climbed from 0.91% to 1.03%, which management attributed to more specialty drugs shipped to health systems and favorable launch timing, so the second quarter will show how much of that gain is structural[3][4]. Second is organic growth in Oncology & Multispecialty once Core Ventures has been consolidated for a full year: segment profit rose 41% in the first quarter but only about 15% excluding Core Ventures, and with the deal now in the comparison base, reported growth will show directly whether organic growth can support full-year profit guidance of 13.5%-17.5%[4]. Third is whether cash flow can keep pace with capital returns: first-quarter operating cash flow was -$220 million and free cash flow was -$372 million, yet the company had already repurchased $2.53 billion of stock and added $3.215 billion of long-term borrowing, so whether first-half cash flow turns positive will decide how credible the $4.5-$4.9 billion full-year free cash flow guidance is[6][3][4].

Company Background and Business Structure

McKesson is a NYSE-listed company founded in 1833 and headquartered in Irving, Texas, and over the past two years it has exited non-core businesses while expanding in specialty care[1]. In April 2025 it paid $875 million in cash for 80% of ophthalmology management services company PRISM Vision, in June 2025 it paid $2.5 billion in cash for 70% of Core Ventures, the management services organization established by Florida Cancer Specialists, and in January 2026 it sold its Norway business for $821 million; it also plans to separate the Medical-Surgical Solutions segment through a tax-free split-off or spin-off[1]. On June 1, 2026, funds managed by Apollo acquired about 13% of that segment through an investment of about $1.25 billion in convertible preferred equity[6]. On October 6, 2026, the company announced that it and CD&R will acquire home infusion provider Option Care Health for $32.05 per share, an enterprise value of about $5.8 billion, with McKesson investing about $1.4 billion for roughly 49% and accounting for the stake under the equity method; the deal is slated to close in the first half of calendar 2027[7]. Trade press has also reported that the company signed an agreement in August 2026 to acquire clinical research and drug commercialization services company Precision Medicine Group for about $2.25 billion, a transaction that does not yet appear in the company filings cited here.

Since the second quarter of fiscal 2026 the company has reported four segments, and revenue is heavily concentrated in North American drug distribution[1]. North American Pharmaceutical generated $336.652 billion of revenue in fiscal 2026, distributing branded, generic, specialty, biosimilar and over-the-counter drugs to customers in the US and Canada and sourcing generics through ClarusONE, its joint venture with Walmart; Oncology & Multispecialty generated $48.423 billion, combining specialty drug distribution to practices with practice management, group purchasing, revenue cycle management and data services; Prescription Technology Solutions generated $5.805 billion; and Medical-Surgical Solutions generated $11.507 billion[1]. Service revenue is less than 1% of revenue in North American Pharmaceutical and Medical-Surgical, about 7% in Oncology & Multispecialty and about 39% in Prescription Technology Solutions, which shows that the first two are essentially pass-through distribution while the last is primarily a technology services business[6].

Customer and supplier concentration shapes both the company's bargaining position and its cash cycle. In fiscal 2026 the ten largest customers, including group purchasing organizations, accounted for about 73% of consolidated revenue, the largest customer CVS for about 24%, and the next two for about 11% and 10%; the ten largest suppliers accounted for about 71% of purchases, and some branded distribution agreements pay a percentage of purchases while others include an inflation-based component[1]. The CVS distribution agreement was extended in fiscal 2023 to June 2027, and Simply Wall St discussed the further extension of that agreement in an October article[1][8]; the agreement in principle reported by trade press would run to June 2032, but a definitive contract has yet to be signed. On the cash side, drafts and accounts payable stood at $63.731 billion on June 30, 2026, more than the combined $30.316 billion of receivables and $26.259 billion of inventory, because drugmakers grant longer payment terms than the company grants its customers[6].

Financial History and Current Position

The fiscal 2026 annual report, for the year ended March 31, 2026, shows fast growth in revenue and segment profit, but a gross margin of only a little over 3%[1]. According to multi-year financial data compiled by Drillr, revenue grew from $263.966 billion in fiscal 2022 to $403.430 billion in fiscal 2026, GAAP operating profit rose from $2.723 billion to $6.454 billion and net income rose from $1.114 billion to $4.762 billion. Fiscal 2026 gross profit was $14.55 billion with a 3.61% gross margin (3.71% in fiscal 2025), including a $210 million LIFO credit and a $23 million antitrust settlement gain, compared with an $82 million LIFO charge and a $444 million gain in fiscal 2025; GAAP segment operating profit was $3.658 billion in North American Pharmaceutical, $1.149 billion in Oncology & Multispecialty, $1.044 billion in Prescription Technology Solutions and $938 million in Medical-Surgical, operating cash flow was $6.155 billion, dividends were $3.17 per share or $381 million in total, and opioid-related settlement payments were $512 million[1].

Results for the first quarter of fiscal 2027, ended June 30, 2026, show profit growing faster than revenue while GAAP earnings were depressed by one-time items[3]. Revenue was $105.38 billion, up 8%, adjusted EPS was $9.93, up 20%, and GAAP diluted EPS was $5.15; adjusted segment operating profit was $894 million in North American Pharmaceutical (+19%), $405 million in Oncology & Multispecialty (+41%), $303 million in Prescription Technology Solutions (+13%) and $195 million in Medical-Surgical (-20%), with net corporate expenses of -$144 million and income before interest and taxes of $1.653 billion, up 16%[3]. Net income attributable to McKesson was $614 million, below $784 million a year earlier, while adjusted earnings were $1.183 billion[3].

The balance sheet took on clearly more leverage in the first quarter as capital returns accelerated[6]. Operating cash flow was -$220 million, capital expenditure was $152 million and free cash flow was -$372 million; the company repurchased $2.53 billion of stock, added $3.215 billion of long-term borrowing and received $1.238 billion in net proceeds from selling the Medical-Surgical minority stake[6][3]. On June 30 cash was $5.164 billion, long-term debt was $8.432 billion (versus $5.259 billion on March 31), the current portion of debt was $1.297 billion, long-term litigation liabilities were $5.058 billion and stockholders' equity was -$4.24 billion; in July the board raised the quarterly dividend from $0.82 to $0.94[6]. Management plans $5 billion of buybacks for the full year and guided to $380-$420 million of interest expense and an 18%-19% effective tax rate[4].

Operating Model

McKesson's revenue is driven mainly by prescription volume and drug prices, and price changes move revenue a great deal while moving profit very little[4]. Consolidated revenue is roughly the sum of North American Pharmaceutical distribution revenue ($86.773 billion in the first quarter), Oncology & Multispecialty specialty distribution and practice services revenue ($14.222 billion), Prescription Technology Solutions technology services and third-party logistics revenue ($1.566 billion) and Medical-Surgical distribution revenue ($2.819 billion)[3]. Distribution revenue is booked at the full drug price, so the January 2026 cuts in branded wholesale acquisition cost (WAC), branded-to-generic conversions and $15 billion of quarterly GLP-1 distribution all change revenue materially; management noted that because most branded drugs are handled under fee-for-service contracts, gross profit and operating profit have historically been far less sensitive to such price changes[4].

On the profit side, what matters is a few basis points of segment margin rather than revenue growth[3]. Adjusted operating profit is roughly each segment's revenue multiplied by its adjusted margin, less corporate expenses: in the first quarter, $86.773 billion at 1.03% gives about $894 million in North American Pharmaceutical, $14.222 billion at 2.85% gives about $405 million in Oncology & Multispecialty, $1.566 billion at 19.35% gives about $303 million in Prescription Technology Solutions and $2.819 billion at 6.92% gives about $195 million in Medical-Surgical, and subtracting $144 million of corporate expenses leaves $1.653 billion[3]. Distribution gross profit comes from manufacturer fees paid as a percentage of purchases, generic sourcing spreads and inflation-based terms, and LIFO inventory accounting passes branded inflation or deflation directly into gross profit; the GAAP figures also include restructuring, acquisition integration, minority-interest redemption value adjustments and litigation items[1][3].

The core of the cash model is negative working capital, which lets revenue growth itself generate a cash float but makes quarters highly volatile[6]. On June 30, payables exceeded receivables plus inventory by about $7.156 billion, compared with about $7.781 billion on March 31; in the first quarter receivables rose $2.374 billion and inventory rose $2.074 billion, only partly offset by a $3.773 billion increase in payables, and $538 million of tax payments pushed operating cash flow negative[6]. The prior year followed the same pattern: operating cash flow was -$918 million in the first quarter of fiscal 2026 but reached $6.155 billion for the full year[6][1]. Capital expenditure is small, opioid settlement payments of roughly $500 million a year run through operating cash flow, and the remaining cash goes mainly to buybacks, dividends and specialty acquisitions[1][6].

Industry and Competitive Position

US drug wholesaling is dominated by McKesson, Cencora (formerly AmerisourceBergen) and Cardinal Health, and competition plays out mainly in renewal pricing for large customers and in generic sourcing costs, with distribution margins long hovering around 1%. McKesson is the largest of the three by revenue, and its largest customer CVS also buys from Cardinal Health, which makes renewal terms the most direct competitive variable among the three. North American Pharmaceutical's 1.03% adjusted margin in the first quarter is in line with that industry level, which indicates that McKesson's unit economics in traditional distribution are not clearly better than its peers'[3].

Differentiation comes mainly from specialty drug channels, community practice networks and services sold to drugmakers. Through The US Oncology Network, Core Ventures, PRISM Vision and its 51% stake in Sarah Cannon Research Institute, McKesson ties specialty drug distribution to practice operations, while Cencora and Cardinal Health each run their own specialty distribution businesses[1]. Prescription Technology Solutions charges drugmakers for electronic prior authorization, price transparency and patient assistance services and earned a 19.35% adjusted margin in the first quarter, which makes it the part of the business least directly comparable across the three[3]. The available material covers only McKesson's own segment data and cannot compare the three companies' margins in specialty drugs and manufacturer services on the same basis, which is the main limitation of this comparison.

Core Debates

North American Pharmaceutical profit rose 19% on 5% revenue growth in the first quarter: is the specialty and health-system mix gain durable, or a one-off from launch timing?

North American Pharmaceutical supplies more than 80% of McKesson's revenue and about half of its segment profit, so the direction of its margin matters more to full-year EPS than its revenue growth[1][3]. The segment generated $336.652 billion of revenue in fiscal 2026 and $894 million of adjusted operating profit in the first quarter of fiscal 2027, nearly half of the $1.797 billion four-segment total; because the margin is only about 1%, each basis point of margin on first-quarter revenue of $86.773 billion is worth roughly $9 million of quarterly profit[1][3]. In August management raised the segment's full-year profit growth guidance to the high end of its 5.5%-9.5% range while flagging accelerated business investment in the second half[4].

The first-quarter numbers show clear margin expansion, but part of what drove it was timing[3]. Segment revenue was $86.773 billion, up 5% from $82.729 billion, while adjusted operating profit rose 19% from $749 million to $894 million and the margin rose 12 basis points from 0.91% to 1.03%[3]. The 10-Q attributed revenue growth to higher volumes from institutional and retail national account customers, partly offset by branded price decreases and branded-to-generic conversions, and noted that profit also benefited from the absence of the prior-year Rite Aid bankruptcy impact[6]. On the call, management attributed profit growth to more specialty drugs shipped to health systems and favorable timing of new branded and generic launches, said June was the strongest month of the quarter, and reported GLP-1 revenue of $15 billion, up 24%[4].

The financial transmission behind this debate is clear, but the durability of each link is unproven[4]. Higher specialty purchasing by health systems and institutional customers, together with new launches, shifts the customer, product and channel mix toward higher unit gross profit, lifts the segment margin and lets profit grow faster than revenue; WAC cuts and branded-to-generic conversions depress revenue, but fee-for-service contracts make gross profit insensitive to price, and GLP-1 adds more to revenue than to profit[4]. The alternative reading is that a large share of first-quarter profit growth came from launch timing and inventory gains ahead of price cuts; as those fade in the second quarter and second-half investment accelerates, profit growth could fall back toward revenue growth, and the definitive terms of the CVS renewal could also give up some margin as the current contract runs only to June 2027[1].

The most direct second-quarter test is whether segment profit growth and margin are still expanding[3][4]. If North American Pharmaceutical adjusted operating profit still grows about 7% or more year over year with a further margin increase, and management continues to credit specialty drugs and health-system channels, the structural explanation will be strengthened; if profit growth drops below 5.5% or the margin contracts year over year, the first-quarter gain will look mainly like a timing effect. GLP-1 revenue growth, and whether CVS signs a definitive agreement and the company discloses its effect on unit economics, are two further signals for this debate.

Once Core Ventures laps its first year, can organic growth in Oncology & Multispecialty sustain the 13.5%-17.5% profit growth guidance?

Oncology & Multispecialty is McKesson's fastest-growing business, with margins above traditional distribution, and it is where the company has concentrated its recent capital allocation[1]. The segment generated $48.423 billion of revenue in fiscal 2026, up 31%, and $1.149 billion of GAAP operating profit, up 50%; over roughly 18 months the company spent about $3.375 billion in cash on PRISM Vision and Core Ventures, and it has announced a roughly $1.4 billion investment in Option Care Health[1][7]. Together with the roughly $2.25 billion Precision Medicine Group acquisition reported by trade press, the return on all this spending must ultimately show up in the segment's organic profit growth.

Reported first-quarter growth was very high, but acquisitions contributed a large part of it[3]. Segment revenue was $14.222 billion, up 33% from $10.658 billion, adjusted operating profit rose 41% from $287 million to $405 million, and the margin rose from 2.69% to 2.85%[3]. On the call, management said that excluding Core Ventures revenue grew 24% and profit about 15%, in line with its long-term targets, that the Florida Cancer Specialists integration had exceeded expectations and that the deal entered the comparison base this quarter[4]. The 10-Q attributed profit growth to specialty pharmaceutical growth and prior-year acquisitions, partly offset by operating expenses to support higher volumes[6].

At the heart of this debate is the mix between low-margin specialty distribution and higher-margin management services[6]. As specialty practices join The US Oncology Network, Core Ventures and PRISM Vision, affiliated physicians and specialty drug use increase, lifting both specialty distribution volume and management services revenue; distribution volume is low-margin pass-through revenue while management services and group purchasing earn higher margins, so their ratio sets the segment margin, and service revenue is currently only about 7% of segment revenue[6]. The alternative reading is that organic revenue growth of 24% against organic profit growth of about 15% shows that growth is coming mainly from low-margin specialty distribution; once the acquisition effect drops out in the second quarter, reported profit growth could fall into the 6%-11% range implied by full-year guidance, and the 40%-plus growth seen earlier would not represent the segment's normal pace[4].

In the second quarter, the questions are which range reported profit growth lands in and how much of the growth comes from existing practices[3]. If segment adjusted operating profit grows 13% or more, mostly organically, with a further year-over-year margin increase, the case for sustained double-digit growth will be supported; if profit growth falls below about 6% or the margin contracts year over year, organic growth will look weaker than full-year guidance assumes. Management's description of new practice signings and penetration of existing practices, and the progress and consolidation timing of Precision Medicine Group and its effect on later year-over-year comparisons, could also shift the reading of this debate.

Prescription Technology Solutions earns about 17% of segment profit on 1.4% of revenue: can GLP-1-driven prior-authorization demand keep supporting 11%-15% profit growth?

Prescription Technology Solutions is McKesson's highest-margin business, and its growth depends on how much drugmakers will pay in service fees to improve prescription access[3]. The segment's adjusted margin was 19.35% in the first quarter, against about 1% in North American Pharmaceutical; it generated $5.805 billion of revenue in fiscal 2026, about 1.4% of consolidated revenue, and $303 million of adjusted operating profit in the first quarter, about 17% of the four-segment total[3][1]. It charges drugmakers fees to help patients complete prior authorization, co-pay assistance and enrollment, so demand depends on new launches and insurance coverage restrictions; if coverage loosens or drugmakers cut patient-support budgets, this high-margin growth will slow[1].

First-quarter profit grew faster than revenue, and the company attributed this to demand for access services[3]. Segment revenue was $1.566 billion, up 9% from $1.434 billion, and the 10-Q attributed revenue growth to higher third-party logistics volumes[6]. Adjusted operating profit rose 13% from $269 million to $303 million and the margin rose from 18.76% to 19.35%, which the company credited to higher demand for Access Solutions; GAAP segment profit was $226 million, held down mainly by $61 million of restructuring charges[3]. On the call, management singled out prior-authorization demand for GLP-1 drugs and said GLP-1 coverage changes have not yet been large enough to affect category growth[4].

The transmission chain in this debate makes profit highly sensitive to GLP-1[4]. Coverage restrictions on new launches and high-demand drugs such as GLP-1s lead drugmakers to buy electronic prior authorization, price transparency and patient assistance services, higher volumes of these high-margin transactions let segment adjusted operating profit grow faster than revenue, and third-party logistics grows with drugmaker outsourcing but at lower margins[4][6]. The alternative reading is that profit growth is heavily concentrated in GLP-1 prior authorizations; once coverage rules settle, drugmakers shift GLP-1s to direct-to-consumer channels or cut patient assistance programs, technology transaction growth would slow before revenue does and margin expansion would stop; because the company does not disclose prior-authorization counts or GLP-1 profit contribution, this cannot yet be verified directly.

In the second quarter, the question is whether profit growth can hold the low end of full-year guidance[4]. Full-year guidance is for 2.5%-6.5% revenue growth and 11%-15% profit growth; if second-quarter adjusted operating profit still grows 11% or more with a further margin increase, and management describes demand extending beyond GLP-1 into other therapeutic areas, the broad-demand explanation will be supported[4]. If profit growth falls below 11% and the margin contracts year over year, demand for the high-margin services is slowing.

Free cash flow was negative in the first quarter while buybacks and deals accelerated: can McKesson's negative working-capital model deliver $4.5-$4.9 billion of free cash flow this year?

McKesson's capital returns rest on negative working capital, and its capital needs in fiscal 2027 are clearly higher than in prior years[6]. On June 30, drafts and accounts payable of $63.731 billion exceeded receivables plus inventory by about $7.156 billion[6]. In fiscal 2026 the company used $6.155 billion of operating cash flow to fund $4.8 billion of buybacks and $381 million of dividends[1]; for fiscal 2027 it plans $5 billion of buybacks, completed $2.53 billion in the first quarter, and announced a roughly $1.4 billion investment in Option Care Health[4][6][7]. Over the same period long-term debt rose from $5.259 billion on March 31 to $8.432 billion, and stockholders' equity was -$4.24 billion[6].

First-quarter cash flow was negative, and capital returns were funded by financing rather than by the quarter's operations[6]. Operating cash flow was -$220 million, against -$918 million a year earlier, as receivables rose $2.374 billion and inventory rose $2.074 billion, partly offset by a $3.773 billion increase in payables, with $538 million of tax payments; capital expenditure was $152 million and free cash flow was -$372 million[6][3]. On the financing side, the company added $3.215 billion of long-term borrowing, Apollo paid about $1.25 billion for about 13% of Medical-Surgical, and buybacks totaled $2.53 billion[6]. Management kept its full-year free cash flow guidance of $4.5-$4.9 billion[4].

The transmission of the negative working-capital model is direct, but it makes quarterly cash flow extremely sensitive to payment timing[6]. Drugmakers' payment terms are longer than customer collection terms and inventory turns, so payables exceed receivables plus inventory and revenue growth enlarges the float; payment timing and stocking within a quarter make cash flow swing widely, and free cash flow, operating cash flow less capital expenditure, then funds buybacks, dividends, acquisitions and roughly $500 million a year of opioid settlement payments[6][1]. The alternative reading is that first-quarter financing was preparing a standalone capital structure for the Medical-Surgical separation, so buybacks were effectively funded by pre-separation financing rather than operating cash; if working capital is not recovered as planned in the second half, the cash needs of buybacks, acquisitions and the separation would push net debt higher.

In the second quarter, the question is whether first-half cumulative cash flow and the float are returning to their normal path[4]. If first-half operating cash flow and free cash flow turn positive, the $4.5-$4.9 billion full-year guidance is maintained, and the September 30 float of payables over receivables plus inventory stays near the roughly $7.156 billion seen on June 30, the cash conversion of the negative working-capital model will be supported[4][6]. If first-half cash flow is still negative or free cash flow guidance is cut, capital returns depend more on borrowing; the pace of buybacks, the funding of Option Care and Precision Medicine Group, and changes in long-term debt are three further items to track.

Risks and Falsifiers

Drug pricing and channel policy are the most direct external risks to the distribution and specialty businesses[1][4]. 340B reform, Inflation Reduction Act pricing changes for Part B drugs, most-favored-nation pricing and the direct-to-consumer manufacturer sales it encourages, and CMS's new certification requirements for wholesaler distribution service fees effective January 1, 2026 could all change how drugmakers pay distributors and how customers buy[1]. Management said it is too early to estimate the financial impact, while the combined $1.299 billion of first-quarter adjusted operating profit in North American Pharmaceutical and Oncology & Multispecialty depends directly on manufacturer fees and specialty channels[4][3]. If calls in the second quarter and beyond confirm that known policy changes have not altered the fee contract structure, and both segments keep expanding margins year over year, the practical impact of this risk will be smaller than feared.

The Medical-Surgical separation brings one-time costs, dis-synergies and minority-interest redemption value adjustments, while the segment's own profit is declining[1][6]. First-quarter Medical-Surgical adjusted operating profit was $195 million, down 20%, and the margin fell from 9.03% to 6.92%, which the company attributed to product mix and one-time administrative expenses[3]. In the same quarter, GAAP results included a $293 million redemption value adjustment and separation-related costs, cutting GAAP EPS from $6.25 to $5.15[3]. If the separation proceeds on schedule, the company stops booking large redemption value adjustments, and the segment's adjusted profit returns to the full-year guidance of 0%-4% growth, this risk will ease[4].

Branded drug pricing policy and CVS renewal terms could squeeze North American Pharmaceutical unit profit at the same time[4][1]. On first-quarter segment revenue of $86.773 billion, each basis point of margin decline costs about $9 million of quarterly profit, and because CVS accounts for about 24% of consolidated revenue, changes in its unit economics fall mainly on this segment[3][1]. If North American Pharmaceutical margins keep expanding year over year in the second and third quarters, and the company maintains full-year profit guidance after a definitive CVS agreement is signed, this risk is falsified.

Oncology & Multispecialty increasingly depends on acquisitions, new deals could mask a slowdown in the existing business, and minority-interest redemption value adjustments keep weighing on GAAP profit[4]. Of the segment's $405 million of first-quarter adjusted profit, about a third of the year-over-year increase came from Core Ventures, and GAAP results in the same quarter included an $81 million minority-interest redemption value adjustment[4][3]. If organic profit growth stays above 13% in the second and third quarters and the gap between GAAP and adjusted profit stops widening, this risk will ease.

Changes in GLP-1 coverage rules, growth in direct-to-consumer manufacturer channels or cuts to patient assistance budgets would reduce demand for prior authorization and access services[4]. Prescription Technology Solutions earned $303 million of adjusted profit in the first quarter, about 17% of the four-segment total, and each percentage point of lower profit growth costs about $3 million on the quarterly base[3]. If segment profit grows more than 11% year over year in both the second and third quarters, and management confirms that demand spans multiple therapeutic areas, this risk is falsified.

Buybacks, acquisitions and pre-separation financing are all moving at once, and if working capital recovery slows, net debt will rise and squeeze room for future capital returns[6]. Planned full-year buybacks of $5 billion plus the roughly $1.4 billion Option Care investment total about 1.3 times the $4.9 billion top of free cash flow guidance, while long-term debt was $8.432 billion on June 30, up $3.173 billion from March 31[4][7][6]. If full-year free cash flow lands within $4.5-$4.9 billion and long-term debt stops rising from its June 30 level, this risk is falsified.

What to Watch Next

• North American Pharmaceutical margin: first-quarter adjusted operating profit was $894 million, up 19%, with a 1.03% margin versus 0.91%[3]. Watch second-quarter profit growth, GLP-1 revenue against the first quarter's $15 billion and a definitive CVS agreement[4]. Growth of about 7% or more with margin expansion confirms the mix story; growth below 5.5% or a margin decline falsifies it.
• Oncology & Multispecialty organic growth: first-quarter adjusted operating profit was $405 million, up 41%, or about 15% excluding Core Ventures, with a 2.85% margin[3][4]. Watch reported growth after the full-year lap, new practice signings and Precision Medicine Group progress. Growth above 13%, mostly organic, confirms; below about 6% or a margin decline falsifies.
• Prescription Technology Solutions demand: first-quarter adjusted operating profit was $303 million, up 13%, with a 19.35% margin[3]. Watch Access Solutions demand outside GLP-1[4]. Growth above 11% with margin expansion confirms; below 11% with margin contraction falsifies.
• Cash conversion and capital deployment: first-quarter free cash flow was -$372 million, the working-capital float about $7.156 billion and long-term debt $8.432 billion[6]. Watch whether the $4.5-$4.9 billion guidance holds and how buybacks and deals are funded[4]. Positive first-half cash flow with guidance intact confirms; continued negative cash flow or a guidance cut falsifies.

Conclusion

McKesson's profit is set by a few basis points of distribution margin, the expansion of its specialty businesses and its high-margin manufacturer services, while its cash depends on the float created by negative working capital[3][6]. In the first quarter of fiscal 2027 the company turned 8% revenue growth into 20% adjusted EPS growth, North American Pharmaceutical's margin rose from 0.91% to 1.03% and Prescription Technology Solutions' margin reached 19.35%, yet operating cash flow was -$220 million, buybacks were $2.53 billion and long-term debt rose to $8.432 billion[3][6]. The central unresolved relationship is how much of the margin expansion comes from durable channel and product mix versus launch timing, acquisition consolidation and phase-specific GLP-1 demand, and whether cash flow can catch up in the second half with capital returns that have already been paid out.

Independent outside views published after the latest results are scarce, and a Simply Wall St article on October 11 is the only one used here[8]. It describes McKesson as a low-margin, high-volume distributor and argues that the extended CVS agreement looks meaningful for short-term visibility on distribution volumes and can reduce renewal uncertainty, but that drug pricing regulation, cybersecurity fallout and any slowdown in GLP-1-related access volumes remain the biggest operational swing factors[8]. That view lines up with the North American Pharmaceutical and Prescription Technology Solutions debates: the renewal improves visibility on revenue from the largest customer but does not answer whether margins can keep expanding or whether GLP-1-driven high-margin services can last; the remaining material mostly restates reported numbers or share-price moves and offers no second independent interpretation, so readers should treat this article as one outside interpretation rather than a market consensus.

Going forward, the combination that would most strengthen the current understanding is second-quarter North American Pharmaceutical profit growth of about 7% or more with further margin expansion, Oncology & Multispecialty profit growth above 13%, mostly organic, after the full-year lap, Prescription Technology Solutions profit growth holding at 11%, and positive first-half free cash flow with the $4.5-$4.9 billion full-year guidance intact[4]. Conversely, if North American Pharmaceutical profit growth falls below 5.5%, Oncology & Multispecialty profit growth drops below about 6%, Prescription Technology Solutions margins contract, or first-half cash flow stays negative while long-term debt keeps rising, the first-quarter improvement will look more like timing and financing, and the current understanding would need a clear downward revision.

Sources

[1] MCK FY2026 10-K filed 2026-05-08 · 2026-05-08 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000927653&type=10-K&dateb=&owner=include&count=40

[2] MCK earnings calendar updated 2026-10-22 · 2026-10-22 · Drillr earnings calendar

[3] MCK Q1 FY2027 8-K filed 2026-08-05 · 2026-08-05 · 8-K · https://investor.mckesson.com/news/default.aspx

[4] MCK Q1 FY2027 earnings call 2026-08-05 · 2026-08-05 · earnings-call · https://investor.mckesson.com/news/default.aspx

[5] Drillr analyst estimates MCK Q2 FY2027 retrieved 2026-10-22 · 2026-10-22 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[6] MCK Q1 FY2027 10-Q filed 2026-08-05 · 2026-08-05 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000927653&type=10-Q&dateb=&owner=include&count=40

[7] MCK 8-K filed 2026-10-06 · 2026-10-06 · 8-K · https://investor.mckesson.com/news/default.aspx

[8] Simply Wall St McKesson CVS extension review 2026-10-11 · 2026-10-11 · Simply Wall St · https://www.webull.com/news/15730372907639808